Does the shingles vaccine protect your heart?

The newer one might. In this Oxford study, adults aged 60 and older who received the recombinant shingles vaccine carried about 9% less heart disease burden over the next 7 years than adults who received the older live vaccine.

That comparison is the whole point. Earlier research suggesting the shingles vaccine is good for your heart compared people who got vaccinated with people who did not. People who show up for vaccines also tend to show up for everything else: blood pressure checks, medication refills, exercise. So the heart benefit could have been the healthier person, not the shot.

This team found a way around that problem. The United States switched quickly from the live attenuated shingles vaccine to the recombinant one. That created a natural experiment. Adults vaccinated in the weeks just before the switch got one vaccine, adults vaccinated just after got the other, and both groups were the kind of people who go get vaccinated. The researchers compared those two groups over the following 7 years.

What the data show

The main outcome was a combined measure of ischemic heart disease, heart failure, and ischemic stroke. Instead of simply counting who had an event, the researchers measured burden, meaning how much of those 7 years was lost to heart disease. On that measure, the recombinant vaccine group lost about 9% less time (restricted mean time lost ratio 0.91). The result is very likely a reduction somewhere between 5% and 12% (95% confidence interval 0.88 to 0.95).

Breaking it apart, ischemic heart disease burden was about 10% lower (ratio 0.90, very likely between 6% and 13% lower), and heart failure burden was about 12% lower (ratio 0.88, very likely between 7% and 17% lower). Both of those held in men and women. Ischemic stroke burden was about 12% lower (ratio 0.88) in males only, and the range there was wide enough to include an effect as small as 2%. Atrial fibrillation, an irregular heart rhythm, showed about a 7% lower burden (ratio 0.93). Other cardiac, peripheral, and cerebrovascular outcomes showed no difference at all.

One detail deserves attention: the association attenuated over time. The gap between the two groups was largest early and shrank as the years went on.

Dr. Kumar’s Take

This is a smart study design applied to a real question, and the design is what makes the number worth reading. Comparing one vaccine against another vaccine, rather than against nothing, removes most of the “healthy vaccinee” problem in one move. Both groups walked into a pharmacy for a shot within months of each other.

A 9% reduction in disease burden is a modest effect, not a transformation, and it is still an association drawn from health records rather than a randomized trial. There is also no proof here of a mechanism. Shingles reactivation causes inflammation in blood vessels, and a vaccine that prevents shingles more effectively could plausibly prevent some of that vascular damage, but this study did not test that chain of events.

Worth noting for context: two of the authors disclose consultancy fees from GSK, the company that makes the recombinant vaccine. The authors state GSK had no involvement in the study and did not know about it until the paper was accepted. That does not invalidate anything, and the design is strong enough to stand on its own, but readers deserve to know it.

The authors themselves land in the right place. They call for clinical trials and mechanistic studies rather than declaring the vaccine a heart drug. That is the correct next step.

What this does not prove

Both groups here were vaccinated, so this study says nothing about whether getting a shingles vaccine beats getting none for your heart. It compares two vaccines. It also cannot rule out every difference between people vaccinated before and after the transition, since the groups were not randomly assigned. The narrowing of the effect over time could reflect a real fading benefit, or it could reflect the two groups gradually becoming more alike in other ways. Secondary analyses gave consistent results, which is reassuring, but consistency in an observational design is not the same as proof.

Practical Takeaways

If you are 60 or older and have not had a shingles vaccine, the recombinant version is the one currently used in the United States, and this study adds a possible heart benefit on top of the shingles protection you are already getting.
Do not treat a shingles shot as cardiac care. A 9% difference in disease burden between two vaccines is not heart treatment.
If you were vaccinated years ago with the older live vaccine, this study is not a reason for alarm. It found a relative difference between two vaccines, not harm from the older one.

FAQs

What is the difference between the live and recombinant shingles vaccines?

The live attenuated vaccine used a weakened form of the virus itself to train the immune system. The recombinant vaccine uses a piece of the virus plus an ingredient that boosts the immune response, and it contains no live virus. The United States moved from the first to the second quickly, and that rapid switch created the two comparable groups this study relied on. Anyone getting vaccinated in the United States today is receiving the recombinant version.

What does “cardiovascular burden” mean, and why not just count heart attacks?

Burden here is measured as time lost to disease over the 7 year follow-up, using a method called restricted mean time lost. A simple count treats a heart attack in year one the same as a heart attack in year six. Measuring lost time captures both whether an event happened and how early it happened, which matters when you are asking whether something delayed disease rather than erased it. It is also why the finding is described as 9% less burden rather than 9% fewer events.

Should I ask for the shingles vaccine specifically to protect my heart?

Not on the strength of this study alone. The finding is an association from health records, the effect faded over the follow-up period, and the authors explicitly called for randomized trials before anyone claims a cardioprotective effect. The stronger case for the vaccine remains shingles itself, which is painful and can leave lasting nerve pain in older adults. A possible heart benefit is a reason to be less hesitant, not a reason to reframe the shot as heart medicine.

Bottom Line

Comparing adults who got the recombinant shingles vaccine against adults who got the older live vaccine, Oxford researchers found about 9% less cardiovascular burden over 7 years, with the clearest signals in ischemic heart disease and heart failure. Because both groups chose to be vaccinated, this sidesteps the confounding that made earlier studies hard to trust. It is still observational, the effect is modest, and it faded over time, but it is now a serious enough signal that randomized trials are justified.

Read the full study